See more : Tattooed Chef, Inc. (TTCF) Income Statement Analysis – Financial Results
Complete financial analysis of Pliant Therapeutics, Inc. (PLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pliant Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ScreenPro Security Inc. (SCRN.CN) Income Statement Analysis – Financial Results
- PT Bekasi Fajar Industrial Estate Tbk (BEST.JK) Income Statement Analysis – Financial Results
- Learning 2 Sleep L2S AB (publ) (L2S.ST) Income Statement Analysis – Financial Results
- Fintech Ecosystem Development Corp. (FEXDR) Income Statement Analysis – Financial Results
- Bhagwati Autocast Limited (BGWTATO.BO) Income Statement Analysis – Financial Results
Pliant Therapeutics, Inc. (PLRX)
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.58M | 9.69M | 7.57M | 41.82M | 57.05M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 3.68M | 3.20M | 0.00 | 0.00 | 666.00K | 0.00 |
| Gross Profit | 1.58M | 6.00M | 4.37M | 41.82M | 57.05M | -666.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 61.99% | 57.69% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 127.80M | 96.94M | 77.55M | 66.19M | 47.35M | 24.42M | 14.53M |
| General & Administrative | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Other Expenses | 0.00 | 0.00 | -77.55M | -366.00K | -216.00K | -49.00K | 0.00 |
| Operating Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Cost & Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Interest Income | 24.08M | 4.67M | 272.00K | 478.00K | 816.00K | 688.00K | 16.00K |
| Interest Expense | 1.27M | 791.00K | 272.00K | 366.00K | 216.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.84M | 3.68M | 3.20M | 1.31M | 1.11M | 666.00K | 292.00K |
| EBITDA | -158.23M | -118.85M | -95.73M | -40.34M | -118.00K | -30.25M | -18.06M |
| EBITDA Ratio | -10,014.43% | -1,265.15% | -263.95% | -99.59% | -0.21% | 0.00% | 0.00% |
| Operating Income | -184.15M | -127.20M | -19.99M | -41.65M | -1.23M | -30.92M | -18.35M |
| Operating Income Ratio | -11,654.75% | -1,313.37% | -263.95% | -99.59% | -2.16% | 0.00% | 0.00% |
| Total Other Income/Expenses | 22.81M | 3.88M | 272.00K | 112.00K | 600.00K | 639.00K | 16.00K |
| Income Before Tax | -161.34M | -123.32M | -19.71M | -41.53M | -631.00K | -30.28M | -18.33M |
| Income Before Tax Ratio | -10,211.14% | -1,273.32% | -260.35% | -99.32% | -1.11% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.82M | -1.81M | -1.79M | -816.00K | 639.00K | 2.29M |
| Net Income | -161.34M | -121.50M | -17.91M | -39.75M | 185.00K | -30.28M | -20.62M |
| Net Income Ratio | -10,211.14% | -1,254.50% | -236.49% | -95.05% | 0.32% | 0.00% | 0.00% |
| EPS | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| EPS Diluted | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| Weighted Avg Shares Out | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
| Weighted Avg Shares Out (Dil) | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo...
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced presentations made at the European Respiratory...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following September investor...
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced three upcoming presentations at the European...
Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled
Pliant Therapeutics is a biotech company focused on developing therapies for fibrotic diseases. The company's financials show an increase in R&D and administrative expenses, as well as a net loss, but it has a strong liquidity position. Pliant's pipeline includes...
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.82 per share a year ago.
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF INTEGRIS-PSC Phase 2a 12-week data of bexotegrast in patients with PSC expected in the third quarter of 2023 Initiation of Phase 1 trial of PLN-101095 in patients with...
Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the initiation of BEACON-IPF, a Phase...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following August investor...
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.78 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports